To evaluate 24-hr glucose after OD vs BD AZD1656
Study identifier:D1020C00017
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Randomised, Two Way Cross-over, Single-Blind, Phase I Study to Evaluate 24-hr Glucose Profiles in Patients with T2DM when Dosed OD and BD on Top of Metformin for Four Days with AZD1656
Medical condition
Type II Diabetes
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD1656
Sex
All
Actual Enrollment
36
Study type
Interventional
Age
30 Years - 75 Years
Date
Study Start Date: 01 Jan 2009
Primary Completion Date: 01 May 2009
Study Completion Date: 01 May 2009
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 twice daily during 4 days | Drug: AZD1656 Oral suspension |
| Experimental: 2 once daily during 4 days | Drug: AZD1656 Oral suspension |
Contacts
Investigators
Principal Investigator
Klas Malmberg
AstraZeneca R&D Mölndal
